SEC Company Response from ENANTA PHARMACEUTICALS INC (ENTA) (CIK 0001177648) (ENTA) — Mar 18, 2013
ENANTA PHARMACEUTICALS INC (ENTA) (CIK 0001177648)
Date: March 18, 2013 · CIK: 0001177648 · Accession: 0001193125-13-111530
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-184779
Letter
Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549
Dear Sir/Madam:
Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933 (the “Act”), we, as representatives of the several Underwriters, wish to advise you that 6,704 copies of the Preliminary Prospectus dated March 5, 2013, were distributed during the period March 5, 2013 through 5:00 p.m. New York City Time, March 15, 2013, to prospective underwriters, institutions, dealers and others.
We were advised on January 18, 2013 by the Corporate Financing Department of the Financial Industry Regulatory Authority that it has reviewed the above-captioned proposed offering and that it has determined to raise no objections with respect to the fairness of the terms and arrangements of the offering.
We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934.
In accordance with Rule 461 of the Act, we hereby join in the request of Enanta Pharmaceuticals, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 3:00 p.m. New York City Time on March 20, 2013, or as soon thereafter as practicable.
[Remainder of page intentionally left blank]
Very truly yours,
By:
Show Raw Text
CORRESP 1 filename1.htm Acceleration Request J.P. MORGAN SECURITIES LLC 383 Madison Avenue New York, NY 10179 CREDIT SUISSE SECURITIES (USA) LLC Eleven Madison Avenue New York, NY 10010 March 18, 2013 Re: Enanta Pharmaceuticals, Inc. Registration Statement on Form S-1 Registration File No. 333-184779 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Dear Sir/Madam: Pursuant to Rule 460 of the General Rules and Regulations under the Securities Act of 1933 (the “Act”), we, as representatives of the several Underwriters, wish to advise you that 6,704 copies of the Preliminary Prospectus dated March 5, 2013, were distributed during the period March 5, 2013 through 5:00 p.m. New York City Time, March 15, 2013, to prospective underwriters, institutions, dealers and others. We were advised on January 18, 2013 by the Corporate Financing Department of the Financial Industry Regulatory Authority that it has reviewed the above-captioned proposed offering and that it has determined to raise no objections with respect to the fairness of the terms and arrangements of the offering. We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934. In accordance with Rule 461 of the Act, we hereby join in the request of Enanta Pharmaceuticals, Inc. for acceleration of the effective date of the above-named Registration Statement so that it becomes effective at 3:00 p.m. New York City Time on March 20, 2013, or as soon thereafter as practicable. [Remainder of page intentionally left blank] Very truly yours, By: J.P. MORGAN SECURITIES LLC By: /s/ Sri Kosaraju Name: Sri Kosaraju Title: Managing Director By: CREDIT SUISSE SECURITIES (USA) LLC By: /s/ Charles W. Newton Name: Charles W. Newton Title: Managing Director 2